報價延遲最少15分鐘:2026/04/13 12:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.18 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.38/0.04
|
|
企業價值
8.03B
|
| 資產負債 |
|
每股賬面淨值
-0.48
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
113.29M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States. |
